NASDAQ:DXCM - DexCom Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $516.93
  • Forecasted Upside: -5.86 %
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
▲ +7.82 (1.44%)

This chart shows the closing price for DXCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DexCom Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DXCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DXCM

Analyst Price Target is $516.93
▼ -5.86% Downside Potential
This price target is based on 16 analysts offering 12 month price targets for DexCom in the last 3 months. The average price target is $516.93, with a high forecast of $650.00 and a low forecast of $438.00. The average price target represents a -5.86% upside from the last price of $549.10.

This chart shows the closing price for DXCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 16 polled investment analysts is to buy stock in DexCom. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 15 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/18/2021GuggenheimDowngradeBuy ➝ NeutralMedium
10/1/2021CitigroupBoost Price TargetBuy$530.00 ➝ $630.00Medium
9/16/2021Piper SandlerBoost Price TargetOverweight$550.00 ➝ $650.00High
8/2/2021Morgan StanleyBoost Price TargetEqual Weight$410.00 ➝ $510.00Low
7/30/2021StephensBoost Price TargetOverweight$468.00 ➝ $546.00High
7/30/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$380.00 ➝ $475.00High
7/30/2021SVB LeerinkBoost Price TargetOutperform$485.00 ➝ $500.00High
7/30/2021OppenheimerBoost Price TargetOutperform$500.00 ➝ $525.00High
7/30/2021Canaccord GenuityBoost Price TargetBuy$455.00 ➝ $500.00High
7/30/2021Raymond JamesBoost Price TargetOutperform$466.00 ➝ $515.00High
7/30/2021Robert W. BairdBoost Price TargetOutperform$460.00 ➝ $520.00High
7/30/2021Piper SandlerBoost Price TargetOverweight$500.00 ➝ $550.00High
7/21/2021CowenLower Price TargetOutperform$540.00 ➝ $525.00Low
7/1/2021StephensReiterated RatingBuy$468.00Low
5/28/2021Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$380.00High
5/24/2021BarclaysInitiated CoverageOverweight$500.00Medium
4/30/2021CitigroupBoost Price Target$480.00 ➝ $488.00High
4/30/2021Canaccord GenuityBoost Price TargetBuy$445.00 ➝ $455.00High
4/30/2021Raymond JamesBoost Price TargetOutperform$449.00 ➝ $466.00High
4/15/2021Atlantic SecuritiesInitiated CoverageOverweight$438.00Medium
2/12/2021CitigroupLower Price TargetBuy$485.00 ➝ $480.00Low
2/12/2021OppenheimerBoost Price TargetOutperform$415.00 ➝ $449.00Low
2/12/2021Morgan StanleyBoost Price TargetEqual Weight$402.00 ➝ $410.00Low
2/12/2021Raymond JamesBoost Price TargetOutperform$415.00 ➝ $449.00Low
1/29/2021Piper SandlerBoost Price TargetOverweight$465.00 ➝ $500.00High
1/6/2021UBS GroupUpgradeNeutral ➝ Buy$410.00 ➝ $445.00N/A
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$398.00 ➝ $402.00Low
12/10/2020Canaccord GenuityLower Price TargetBuy$475.00 ➝ $435.00High
12/10/2020Raymond JamesReiterated RatingBuyHigh
11/20/2020Piper SandlerReiterated RatingBuy$465.00Medium
10/28/2020Stifel NicolausLower Price TargetBuy$500.00 ➝ $475.00High
10/28/2020Canaccord GenuityLower Price TargetBuy$500.00 ➝ $475.00High
10/28/2020Raymond JamesLower Price TargetOutperform$450.00 ➝ $438.00High
10/28/2020Morgan StanleyLower Price TargetEqual Weight$428.00 ➝ $398.00High
10/2/2020Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$420.00 ➝ $350.00High
7/29/2020UBS GroupBoost Price TargetNeutral$335.00 ➝ $400.00High
7/29/2020Morgan StanleyBoost Price TargetEqual Weight$377.00 ➝ $428.00Low
7/29/2020Canaccord GenuityBoost Price TargetBuy$435.00 ➝ $500.00Medium
7/29/2020Raymond JamesBoost Price TargetOutperform$395.00 ➝ $450.00Low
7/29/2020Stifel NicolausBoost Price TargetBuy$385.00 ➝ $500.00Low
7/29/2020SVB LeerinkBoost Price TargetEqual Weight ➝ Outperform$465.00 ➝ $485.00Medium
7/29/2020CitigroupBoost Price TargetBuy$440.00 ➝ $485.00Medium
7/29/2020Piper SandlerBoost Price TargetOverweight$450.00 ➝ $465.00Medium
7/28/2020OppenheimerInitiated CoverageBuy$360.00 ➝ $445.00High
7/28/2020Bank of AmericaReiterated RatingBuy$500.00High
7/27/2020JPMorgan Chase & Co.Boost Price TargetOverweight$360.00 ➝ $450.00Medium
7/7/2020CowenBoost Price TargetPositive ➝ Outperform$430.00 ➝ $450.00Low
6/17/2020Bank of AmericaBoost Price TargetBuy$375.00 ➝ $500.00Low
6/9/2020Raymond JamesBoost Price TargetOutperform$360.00 ➝ $395.00High
6/3/2020CitigroupBoost Price TargetAverage ➝ Buy$361.00 ➝ $440.00Medium
5/27/2020Piper SandlerBoost Price TargetOverweight$375.00 ➝ $450.00High
5/14/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$420.00Low
4/30/2020UBS GroupBoost Price TargetNeutral$275.00 ➝ $335.00Medium
4/29/2020GuggenheimBoost Price TargetBuy$385.00 ➝ $395.00High
4/29/2020CitigroupBoost Price TargetBuy$330.00 ➝ $361.00High
4/29/2020Morgan StanleyBoost Price TargetEqual Weight$278.00 ➝ $377.00Medium
4/29/2020JPMorgan Chase & Co.Boost Price TargetOverweight$300.00 ➝ $360.00Medium
4/29/2020Stifel NicolausBoost Price TargetBuy$270.00 ➝ $385.00Medium
4/29/2020OppenheimerBoost Price TargetOutperform$305.00 ➝ $360.00High
4/29/2020CowenBoost Price TargetOutperform$300.00 ➝ $360.00High
4/29/2020Robert W. BairdBoost Price TargetOutperform$296.00 ➝ $373.00High
4/29/2020Piper SandlerBoost Price TargetOverweight$300.00 ➝ $375.00High
4/29/2020BTIG ResearchReiterated RatingHoldHigh
4/27/2020Raymond JamesBoost Price TargetOutperform$288.00 ➝ $350.00Low
4/24/2020SVB LeerinkBoost Price TargetOutperform$316.00 ➝ $385.00Medium
3/27/2020Morgan StanleyBoost Price TargetEqual Weight$270.00 ➝ $278.00High
3/23/2020StephensLower Price TargetOverweight$300.00 ➝ $240.00Low
3/6/2020OppenheimerBoost Price TargetOutperform$285.00 ➝ $305.00Low
3/4/2020CitigroupInitiated CoverageBuy$330.00 ➝ $330.00Low
2/18/2020Morgan StanleyBoost Price TargetEqual Weight$225.00 ➝ $270.00High
2/14/2020Piper SandlerBoost Price Target$230.00 ➝ $300.00Low
2/14/2020CfraBoost Price TargetHold$205.00 ➝ $258.00High
2/14/2020OppenheimerBoost Price TargetOutperform$250.00 ➝ $285.00High
2/14/2020CowenReiterated RatingOutperform$250.00 ➝ $300.00High
2/14/2020GuggenheimReiterated RatingBuy$245.00 ➝ $300.00High
2/14/2020Canaccord GenuityBoost Price TargetBuy$255.00 ➝ $300.00High
2/14/2020StephensBoost Price TargetOverweight$255.00 ➝ $300.00High
2/14/2020UBS GroupBoost Price TargetNeutral$250.00 ➝ $275.00High
2/14/2020Raymond JamesBoost Price TargetOutperform$258.00 ➝ $288.00High
2/14/2020Stifel NicolausBoost Price TargetBuy$250.00 ➝ $300.00High
1/7/2020CowenReiterated RatingBuy$250.00High
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$215.00 ➝ $255.00Low
12/18/2019Bank of AmericaReiterated RatingBuy$220.00 ➝ $250.00Low
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$202.00 ➝ $225.00Medium
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$230.00Medium
11/18/2019Piper Jaffray CompaniesReiterated RatingOverweightHigh
11/7/2019OppenheimerBoost Price Target$180.00 ➝ $205.00Medium
11/7/2019Canaccord GenuityBoost Price TargetBuy$185.00 ➝ $195.00High
11/7/2019Raymond JamesBoost Price TargetOutperform$172.00 ➝ $189.00High
11/7/2019Robert W. BairdBoost Price TargetOutperform$195.00 ➝ $240.00High
11/7/2019Jefferies Financial GroupBoost Price TargetBuy$180.00 ➝ $200.00High
11/7/2019JPMorgan Chase & Co.Reiterated RatingOverweight$190.00 ➝ $215.00High
11/7/2019GuggenheimUpgradeNeutral ➝ BuyHigh
10/22/2019Stifel NicolausInitiated CoverageBuy$190.00High
9/23/2019Piper Jaffray CompaniesSet Price TargetBuy$182.00Medium
9/3/2019BMO Capital MarketsBoost Price TargetOutperform$180.00 ➝ $190.00Low
8/29/2019Robert W. BairdBoost Price TargetOutperform$186.00 ➝ $195.00Low
8/1/2019OppenheimerBoost Price Target$167.00 ➝ $180.00Medium
8/1/2019Bank of AmericaBoost Price TargetBuy$162.00 ➝ $185.00Medium
8/1/2019Robert W. BairdBoost Price TargetOutperform$180.00 ➝ $186.00High
8/1/2019JPMorgan Chase & Co.Boost Price TargetOverweight$170.00 ➝ $190.00High
8/1/2019UBS GroupBoost Price TargetNeutral$140.00 ➝ $160.00High
8/1/2019Raymond JamesBoost Price TargetOutperform$150.00 ➝ $172.00High
8/1/2019BTIG ResearchReiterated RatingHoldHigh
8/1/2019Canaccord GenuityBoost Price TargetBuy$160.00 ➝ $185.00High
7/31/2019Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Positive$173.00 ➝ $182.00High
7/15/2019Piper Jaffray CompaniesSet Price TargetBuy$173.00High
6/6/2019Northland SecuritiesReiterated RatingHold$125.00High
5/2/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$167.00 ➝ $172.00High
5/2/2019Raymond JamesLower Price TargetOutperform ➝ Outperform$160.00 ➝ $150.00High
5/1/2019Piper Jaffray CompaniesBoost Price TargetOverweight$173.00High
4/30/2019UBS GroupLower Price TargetNeutral ➝ Neutral$150.00 ➝ $140.00High
2/25/2019Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$135.00 ➝ $160.00Low
2/22/2019CowenBoost Price TargetOutperform$150.00 ➝ $175.00High
2/22/2019Canaccord GenuityBoost Price TargetBuy$140.00 ➝ $160.00High
1/9/2019Piper Jaffray CompaniesBoost Price TargetAverage ➝ Overweight$165.00High
1/8/2019UBS GroupBoost Price TargetNeutral ➝ Neutral$135.00 ➝ $140.00Medium
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$150.00 ➝ $135.00High
12/6/2018OppenheimerSet Price TargetBuy$150.00Medium
11/27/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$135.00Medium
11/21/2018OppenheimerReiterated RatingBuyMedium
11/7/2018Jefferies Financial GroupBoost Price TargetBuy$148.00Low
11/7/2018StephensBoost Price TargetOverweight$170.00 ➝ $160.00Low
11/7/2018Piper Jaffray CompaniesBoost Price TargetOverweight$157.00Low
11/7/2018OppenheimerSet Price TargetBuy$150.00High
10/23/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $150.00Low
10/19/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$125.00High
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$130.00 ➝ $150.00High
9/12/2018Northland SecuritiesUpgradeUnder Perform ➝ Market PerformHigh
8/23/2018Robert W. BairdBoost Price TargetOutperform ➝ Positive$140.00 ➝ $160.00Low
8/23/2018StephensBoost Price TargetOverweight ➝ Overweight$135.00 ➝ $160.00Low
8/23/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$125.00 ➝ $150.00Low
8/15/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$127.00 ➝ $145.00High
8/6/2018Berenberg BankUpgradeHold ➝ Buy$140.00Low
8/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$70.00 ➝ $130.00Low
8/2/2018StephensReiterated RatingBuy$135.00Low
8/2/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$106.00 ➝ $127.00High
8/2/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$105.00 ➝ $125.00High
8/2/2018CowenBoost Price TargetOutperform$110.00 ➝ $120.00High
8/2/2018BMO Capital MarketsBoost Price TargetOutperformer ➝ Outperform$112.00 ➝ $125.00High
8/2/2018JPMorgan Chase & Co.Boost Price TargetOverweight$140.00High
8/2/2018Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$115.00 ➝ $125.00High
8/2/2018OppenheimerSet Price TargetBuy$85.00 ➝ $125.00High
8/2/2018Piper Jaffray CompaniesBoost Price TargetOverweight$150.00High
7/10/2018BMO Capital MarketsBoost Price TargetOutperform$112.00Low
7/2/2018Raymond JamesUpgradeMarket Perform ➝ OutperformMedium
6/28/2018Canaccord GenuityBoost Price TargetBuy$85.00 ➝ $105.00Medium
6/12/2018Piper Jaffray CompaniesBoost Price TargetOverweight$116.00Low
6/8/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$80.00 ➝ $115.00Medium
5/11/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$100.00Medium
5/4/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $70.00N/A
5/3/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$81.00 ➝ $85.00High
5/3/2018OppenheimerBoost Price TargetOutperform$80.00 ➝ $85.00High
5/3/2018BMO Capital MarketsBoost Price TargetOutperformer ➝ Outperformer$78.00 ➝ $86.00High
5/3/2018BTIG ResearchReiterated RatingHoldHigh
4/9/2018StephensReiterated RatingBuy$78.00Medium
4/4/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$74.69 ➝ $57.00High
4/3/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
3/29/2018Canaccord GenuityBoost Price TargetBuy ➝ Positive$71.00 ➝ $80.00Medium
3/29/2018BMO Capital MarketsUpgradeOutperform$78.00Medium
3/29/2018OppenheimerSet Price TargetBuy$67.00 ➝ $80.00Medium
3/29/2018Piper Jaffray CompaniesSet Price TargetBuy$80.00Medium
3/23/2018Piper Jaffray CompaniesSet Price TargetBuy$78.00High
3/23/2018Robert W. BairdUpgradeNeutral ➝ Outperform$58.00High
3/12/2018Piper Jaffray CompaniesReiterated RatingBuyLow
3/4/2018Northcoast ResearchReiterated RatingBuyHigh
2/28/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$62.00 ➝ $71.00High
2/28/2018OppenheimerSet Price TargetBuy$67.00Medium
2/26/2018Piper Jaffray CompaniesSet Price TargetBuy$60.00Low
2/12/2018OppenheimerSet Price TargetBuy$72.00 ➝ $67.00Low
1/16/2018Northland SecuritiesReiterated RatingSell$40.00Low
1/8/2018BarclaysReiterated RatingHold$60.00High
1/4/2018Northland SecuritiesDowngradeMarket Perform ➝ Under Perform$85.00Low
12/22/2017Jefferies Financial GroupBoost Price TargetTop Pick ➝ Buy$58.00 ➝ $70.00Low
12/12/2017BMO Capital MarketsBoost Price TargetOutperform$74.00Medium
11/3/2017Morgan StanleyLower Price TargetNeutral$72.00 ➝ $52.00N/A
11/2/2017BarclaysLower Price TargetEqual Weight$60.00 ➝ $57.00N/A
11/2/2017Northland SecuritiesReiterated RatingHold$50.00N/A
10/4/2017WedbushReiterated RatingBuy$76.00Low
9/29/2017SVB LeerinkReiterated RatingBuy$85.00 ➝ $57.00High
9/29/2017Raymond JamesDowngradeOutperform ➝ Mkt PerformHigh
9/28/2017Piper Jaffray CompaniesReiterated RatingBuy$87.00High
9/28/2017StephensReiterated RatingBuy$83.00 ➝ $70.00High
9/28/2017BarclaysReiterated RatingEqual Weight$76.00 ➝ $60.00High
9/28/2017OppenheimerLower Price TargetOutperform$92.00 ➝ $85.00High
9/28/2017Robert W. BairdLower Price TargetNeutral ➝ Neutral$79.00 ➝ $58.00High
9/28/2017Northland SecuritiesDowngradeOutperform ➝ Market Perform$85.00 ➝ $60.00High
9/28/2017CowenLower Price TargetOutperform$90.00 ➝ $64.00High
9/28/2017BMO Capital MarketsReiterated RatingOutperform$90.00 ➝ $62.00High
9/28/2017Canaccord GenuityReiterated RatingBuy$90.00 ➝ $69.00High
9/28/2017Raymond JamesReiterated RatingOutperform ➝ Market Perform$76.00 ➝ $49.50High
9/28/2017WedbushReiterated RatingOutperform ➝ Outperform$85.00 ➝ $76.00High
9/28/2017Jefferies Financial GroupReiterated RatingBuy$91.00High
9/28/2017CitigroupDowngradeOutperform ➝ Market PerformHigh
9/28/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$93.00 ➝ $71.00High
9/26/2017Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$85.00Low
9/15/2017BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$76.00Medium
9/10/2017Robert W. BairdReiterated RatingHold$79.00High
9/8/2017BMO Capital MarketsReiterated RatingBuy$90.00High
9/8/2017Piper Jaffray CompaniesReiterated RatingOverweight$87.00Low
8/22/2017Canaccord GenuityReiterated RatingBuy$90.00Low
8/16/2017Piper Jaffray CompaniesReiterated RatingOverweight$87.00 ➝ $78.00Medium
8/8/2017BMO Capital MarketsReiterated RatingOutperform$105.00 ➝ $90.00Low
8/2/2017BMO Capital MarketsReiterated RatingOutperform$105.00 ➝ $90.00Low
8/2/2017StephensReiterated RatingOverweight$95.00 ➝ $83.00High
8/2/2017OppenheimerSet Price TargetBuy$98.00 ➝ $92.00High
7/14/2017CowenReiterated RatingBuy$90.00Medium
7/13/2017BMO Capital MarketsReiterated RatingBuy$105.00Medium
7/12/2017Piper Jaffray CompaniesReiterated RatingBuy$78.00Low
6/7/2017Canaccord GenuityReiterated RatingBuy$90.00Low
5/22/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$78.00Medium
5/9/2017Jefferies Financial GroupLower Price TargetBuy$91.00Low
5/7/2017B. RileyReiterated RatingBuy$95.00High
5/3/2017OppenheimerSet Price TargetBuy$98.00High
5/3/2017Canaccord GenuityLower Price TargetBuy ➝ Buy$95.00 ➝ $90.00High
5/3/2017BTIG ResearchDowngradeBuy ➝ NeutralHigh
5/2/2017B. RileyReiterated RatingBuy$95.00High
4/27/2017B. RileyReiterated RatingBuy$95.00High
4/27/2017William BlairReiterated RatingOutperformLow
4/18/2017CowenReiterated RatingOutperform$90.00Low
4/13/2017OppenheimerReiterated RatingBuyLow
4/4/2017Royal Bank of CanadaReiterated RatingOutperform$87.00Medium
3/22/2017OppenheimerReiterated RatingBuyLow
3/6/2017B. RileyReiterated RatingBuy$95.00N/A
3/1/2017B. RileyReiterated RatingBuy$95.00N/A
3/1/2017Northcoast ResearchReiterated RatingBuyN/A
3/1/2017OppenheimerSet Price TargetBuy$98.00N/A
3/1/2017Jefferies Financial GroupBoost Price TargetBuy$80.00 ➝ $91.00N/A
2/18/2017B. RileyReiterated RatingBuy$94.00N/A
2/16/2017Robert W. BairdReiterated RatingNeutral$79.00N/A
2/13/2017B. RileyReiterated RatingBuy$94.00N/A
2/10/2017Canaccord GenuityReiterated RatingBuy$95.00N/A
1/23/2017Canaccord GenuitySet Price TargetBuy$95.00N/A
1/13/2017OppenheimerReiterated RatingBuy$98.00N/A
1/13/2017BTIG ResearchReiterated RatingBuy$92.00N/A
1/11/2017WedbushReiterated RatingOutperform$85.00N/A
1/10/2017Canaccord GenuityReiterated RatingBuyN/A
1/3/2017Morgan StanleyDowngradeOverweight ➝ Equal Weight$87.00 ➝ $66.00N/A
12/21/2016Canaccord GenuityReiterated RatingBuy$70.00N/A
12/20/2016B. RileyUpgradeBuy$84.00N/A
12/19/2016OppenheimerUpgradeMarket Perform ➝ Outperform$84.00N/A
12/19/2016UBS GroupUpgradeMarket Perform ➝ OutperformN/A
12/15/2016B. RileyUpgradeNeutral ➝ Buy$84.00N/A
11/14/2016Canaccord GenuitySet Price TargetBuy$70.00N/A
11/7/2016B. RileyReiterated RatingNeutral$84.00N/A
11/3/2016SVB LeerinkReiterated RatingOutperform$115.00 ➝ $100.00N/A
11/2/2016B. RileyReiterated RatingNeutral$84.00N/A
11/2/2016OppenheimerSet Price TargetHold$84.00N/A
11/2/2016Canaccord GenuityLower Price TargetBuy$100.00 ➝ $70.00N/A
11/2/2016WedbushReiterated RatingOutperform$100.00 ➝ $112.00N/A
10/31/2016BTIG ResearchUpgradeNeutral ➝ Buy$92.00N/A
(Data available from 10/19/2016 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 11 very positive mentions
  • 23 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 11 very positive mentions
  • 23 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
DexCom logo
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $549.10
Low: $545.00
High: $552.82

50 Day Range

MA: $535.44
Low: $490.26
High: $572.73

52 Week Range

Now: $549.10
Low: $305.63
High: $579.00


22,833 shs

Average Volume

740,095 shs

Market Capitalization

$53.12 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of DexCom?

The following equities research analysts have issued research reports on DexCom in the last year: Atlantic Securities, Barclays PLC, Canaccord Genuity, Citigroup Inc., Cowen Inc, Guggenheim, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Stephens, Stifel Nicolaus, SVB Leerink LLC, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for DXCM.

What is the current price target for DexCom?

15 Wall Street analysts have set twelve-month price targets for DexCom in the last year. Their average twelve-month price target is $516.93, suggesting a possible downside of 5.9%. Piper Sandler has the highest price target set, predicting DXCM will reach $650.00 in the next twelve months. Atlantic Securities has the lowest price target set, forecasting a price of $438.00 for DexCom in the next year.
View the latest price targets for DXCM.

What is the current consensus analyst rating for DexCom?

DexCom currently has 3 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DXCM will outperform the market and that investors should add to their positions of DexCom.
View the latest ratings for DXCM.

What other companies compete with DexCom?

How do I contact DexCom's investor relations team?

DexCom's physical mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company's listed phone number is (858) 200-0200 and its investor relations email address is [email protected] The official website for DexCom is